UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2012
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-51531 | 94-3295878 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 395 Oyster Point Boulevard, Suite 400 South San Francisco, California |
94080 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (650) 266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
The 2012 Annual Meeting of Stockholders (the “Annual Meeting”) of Sunesis Pharmaceuticals, Inc. was held on June 5, 2012. Proxies for the Annual Meeting were solicited by our Board of Directors (the “Board”) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Board’s solicitation. There were 46,924,232 shares of common stock entitled to vote at the Annual Meeting. A total of 40,270,997 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the meeting were as follows:
Proposal No. 1
Edward Hurwitz, Helen S. Kim and Dayton Misfeldt were elected as directors to hold office until the 2015 Annual Meeting of Stockholders by the following vote:
| Nominee |
For |
Withheld |
Broker Non-Votes | |||
| Edward Hurwitz |
24,948,008 | 3,140,022 | 12,182,967 | |||
| Helen S. Kim |
27,732,741 | 355,289 | 12,182,967 | |||
| Dayton Misfeldt |
25,390,045 | 2,697,985 | 12,182,967 |
In addition to the directors elected above, James W. Young, Ph.D., Steven B. Ketchum, Ph.D. and Homer L. Pearce, Ph.D. will continue to serve as directors until the 2013 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal. Matthew K. Fust, David C. Stump, M.D. and Daniel N. Swisher, Jr. will continue to serve as directors until the 2014 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal.
Proposal No. 2
The selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2012 was ratified by the following vote:
| For |
Against |
Abstain | ||
| 40,156,762 |
69,614 | 44,621 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUNESIS PHARMACEUTICALS, INC. | ||||
| Dated: June 11, 2012 |
||||
| By: | /s/ Eric H. Bjerkholt | |||
| Eric H. Bjerkholt | ||||
| Executive Vice President, Corporate Development and Financing, Chief Financial Officer and Corporate Secretary | ||||